The once-daily oral drug, a SARS-CoV-2 main protease inhibitor developed by Shionogi, is registered in Japan and Singapore ...

Protease inhibitors are a promising strategy for enhancing herbivore resistance in plants, which is crucial for addressing the significant yield losses in crops such as tea plants due to insect ...

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.

Ratutrelvir, a ritonavir-free Main protease (Mpro/3CL) inhibitor, was discovered and developed ab initio from target to clinic by ChemDiv's medicinal chemistry and virology services teams. Leveraging ...